Shandong Xinhua Pharmaceutical Company Limited
0719.HKHKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$5.77
+HK$0.03 · +0.52%
0719.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteShandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Wen Hui Xu
- Listed since
- Jan 4, 2000
- Employees
- 7,240
Market position
Day range
Current HK$5.77
52-week range
Current HK$5.77
- Open
- HK$5.74
- Previous close
- HK$5.74
- Volume
- 152K
- 0.1× average
- Average volume
- 1.53M
- Average daily volume
- Market cap
- 8.69B HKD
- Beta
- -0.03
- Market reference 1
- 50-day average
- HK$5.9673
- -3.31% below average
- 200-day average
- HK$6.4862
- -11.04% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 4B CNY
- P/E (TTM)
- 35.95×
- P/B (TTM)
- 1.76×
- P/S (TTM)
- 0.78×
- EV / EBITDA
- 4.04×
- Earnings yield
- 7.10%
- Free cash flow yield
- 10.24%
- Dividend yield
- 1.11%
Profitability & efficiency
- Gross margin
- 18.63%
- Operating margin
- 3.99%
- Net margin
- 2.99%
- Return on equity
- 5.56%
- Return on assets
- 3.15%
- Return on invested capital
- 4.03%
Financial health
- Debt / equity
- 0.36×
- Current ratio
- 1.43×
- Altman Z-score
- 2.92
- Piotroski F-score
- 7 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.75B CNY | 8.47B CNY | 8.1B CNY | 7.5B CNY | 6.56B CNY |
| Cost of goods sold | 7.11B CNY | 6.42B CNY | 5.78B CNY | 5.47B CNY | 4.79B CNY |
| Gross profit | 1.64B CNY | 2.04B CNY | 2.32B CNY | 2.04B CNY | 1.77B CNY |
| Research and development | 440.18M CNY | 413.18M CNY | 419.24M CNY | 345.66M CNY | 341.37M CNY |
| Selling, general, and administrative | 340.79M CNY | 607.61M CNY | 1.3B CNY | 814.86M CNY | 688.89M CNY |
| Operating expenses | 1.23B CNY | 1.51B CNY | 1.79B CNY | 1.49B CNY | 1.27B CNY |
| Interest income | 7.49M CNY | 11.13M CNY | 9.38M CNY | 10.46M CNY | 8.78M CNY |
| Interest expense | 43.33M CNY | 39.74M CNY | 41.15M CNY | 49.71M CNY | 53.1M CNY |
| Depreciation and amortization | 587.52M CNY | 540.95M CNY | 516.94M CNY | 484.81M CNY | 434.33M CNY |
| Operating income | 363.98M CNY | 534.37M CNY | 534.58M CNY | 476.71M CNY | 425.59M CNY |
| Net income | 289.89M CNY | 470.02M CNY | 496.51M CNY | 411.06M CNY | 348.55M CNY |
Company facts updated Aug 25, 2026.
Earnings
- EPS beat rate
- 0%
- 0 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -37.47%
- 6 comparable reports
- Latest EPS result
- 0.2
- Estimate 0.2 · Met by 0.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2731
2025 complete year+51.7% since 2021
2026 partial: HK$0.1725
HK$0.1801
2,021
HK$0.1758
2,022
HK$0.2189
2,023
HK$0.3014
2,024
HK$0.2731
2,025
HK$0.1725
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 10, 2026 | HK$0.1725Annual | Jul 13, 2026 | Jul 31, 2026 |
Dividend | Jun 27, 2025 | HK$0.2731Semi-Annual | Jun 30, 2025 | Jul 18, 2025 |
Dividend | Sep 4, 2024 | HK$0.0273Semi-Annual | Sep 5, 2024 | Sep 27, 2024 |
Dividend | Jul 10, 2024 | HK$0.2741Semi-Annual | Jul 11, 2024 | Jul 30, 2024 |
Dividend | Jul 7, 2023 | HK$0.2189Annual | Jul 10, 2023 | Jul 26, 2023 |
Dividend | Jul 15, 2022 | HK$0.1758Annual | Jul 18, 2022 | Aug 5, 2022 |
Ex-dividend Jul 10, 2026
HK$0.1725
Annual
Record Jul 13, 2026 · Payment Jul 31, 2026
Ex-dividend Jun 27, 2025
HK$0.2731
Semi-Annual
Record Jun 30, 2025 · Payment Jul 18, 2025
Ex-dividend Sep 4, 2024
HK$0.0273
Semi-Annual
Record Sep 5, 2024 · Payment Sep 27, 2024
Ex-dividend Jul 10, 2024
HK$0.2741
Semi-Annual
Record Jul 11, 2024 · Payment Jul 30, 2024
Ex-dividend Jul 7, 2023
HK$0.2189
Annual
Record Jul 10, 2023 · Payment Jul 26, 2023
Ex-dividend Jul 15, 2022
HK$0.1758
Annual
Record Jul 18, 2022 · Payment Aug 5, 2022
0719.HK peers
ETFs holding 0719.HK
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Emerging Markets Small Cap ETFEWX162.03K0.02%687.92M USD0.65%$72.70+1.37%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM159.68K0.00%9.4B USD0.39%$40.065+1.35%
Dimensional - Emerging Core Equity Market ETFDFAE137.7K0.00%9.88B USD0.29%$39.555+1.35%
Dimensional World ex U.S. Core Equity 2 ETFDFAX101.96K0.00%12.56B USD0.28%$38.3026+0.90%
Dimensional - Emerging Markets Value ETFDFEV51.27K0.00%2.09B USD0.46%$42.195+1.28%State Street SPDR S&P Emerging Markets Small Cap ETFEWX- Market value
- 162.03K
- Weight
- 0.02%
- AUM
- 687.92M USD
- Expense ratio
- 0.65%
- Price / 1D
- $72.70+1.37%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- Market value
- 159.68K
- Weight
- 0.00%
- AUM
- 9.4B USD
- Expense ratio
- 0.39%
- Price / 1D
- $40.065+1.35%
Dimensional - Emerging Core Equity Market ETFDFAE- Market value
- 137.7K
- Weight
- 0.00%
- AUM
- 9.88B USD
- Expense ratio
- 0.29%
- Price / 1D
- $39.555+1.35%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 101.96K
- Weight
- 0.00%
- AUM
- 12.56B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.3026+0.90%
Dimensional - Emerging Markets Value ETFDFEV- Market value
- 51.27K
- Weight
- 0.00%
- AUM
- 2.09B USD
- Expense ratio
- 0.46%
- Price / 1D
- $42.195+1.28%
Continue in GoAI
Research 0719.HKresearch.disclaimer